42 results about "Dengue hemorrhagic fever" patented technology

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.

The invention relates to the technical field of biological detection, in particular to a detection method of hemorrhagic fever with renal syndrome IgM (immunoglobulin M) antibodies and a reagent kit. The detection method comprises the steps that hemorrhagic fever with renal syndrome antigens are fixed on a membrane; to-be-detected serum is added; the hemorrhagic fever with renal syndrome IgM antibodies in the to-be-detected serum are combined with the antigens fixed on the membrane; gold labeled operating fluid containing mouse anti-human IgM monoclonal antibodies is added; the mouse anti-human IgM monoclonal antibodies are combinec with the hemorrhagic fever with renal syndrome IgM antibodies in the to-be-detected serum; a red color is shown; scrubbing liquid is added finally; and the redundant gold labeled operating fluid and other impurities are washed out. The reagent kit has the characteristics of longer quality guarantee period, less cross reaction, better color rendering performance and the like.

The present invention relates to a substituted-quinoline-2-formaldehyde-phenylhydrazone derivative and a preparation method and application thereof, and in particular relates to a novel 4-acyl-quinoline-2-formaldehyde-phenylhydrazone derivative, and a preparation method and application thereof to preparation of therapeutic drugs for dengue fever and dengue hemorrhagic fever caused by dengue virus. A structure of the compound is shown as a formula 1. The compound can be used as a protease inhibitor for a dengue virus NS2B-NS3, so as to block further proliferation of the dengue virus in a host.

The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.

Novel compositions comprising viral fusion inhibition compounds and viral replication inhibition compounds as well as methods of their use are disclosed. The novel compositions are useful, inter alia, in the prevention, inhibition and / or treatment of Dengue Fever (DF) or Dengue Hemorrhagic Fever (DHF).

A Chinese medicine for treating epidemic hemorrhagic fever is prepared from 16 Chinese-medicinal materials including cinammon twigs, scutellaria root, prepared pinellia tuber, red peony root, etc. Its advantages include high cure rate (100%), and no complication and sequela.

The invention discloses the application of BRCA2 gene and the expression product in preparing a diagnostic product. The diagnostic product can be used for the diagnosis of dengue fever and dengue hemorrhagic fever. By detecting the level of the BRCA2 gene and the expression product, it is possible to determine the risk of dengue fever and dengue hemorrhagic fever in the subject or the status of dengue fever and dengue hemorrhagic fever. The diagnostic product uses the peripheral blood of a subject as a detection object, and can achieve the non-invasive, rapid, sensitive and accurate diagnosticresults.

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner. We show that epitope specific T cells can be activated in vivo in transgenic mice and in vitro in seropositive and seronegative individuals and that these T cells are functional, recognizing peptide pulsed and dengue virus infected cells in a pro-inflammatory and cytotoxic manner. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and may serve as a universal vaccine candidate complementary to current vaccines in trial.

The invention discloses a CMIP gene capable of being used as a molecular marker for distinguishing Dengue fever and Dengue hemorrhagic fever. By a high-throughput sequencing and RT-PCR method, the CMIP gene has significant expression difference in blood of normal people and patients with Dengue fever and Dengue hemorrhagic fever, i.e., whether a subject suffers the Dengue fever or the Dengue hemorrhagic fever can be judged by detecting the expression condition of the CMIP gene in the blood. According to the correlation of the Dengue fever and the Dengue hemorrhagic fever, the invention develops a kit for diagnosing the Dengue fever and the Dengue hemorrhagic fever. The kit is used for performing the Dengue fever and Dengue hemorrhagic fever diagnosis by detecting the CMIP gene expression.The diagnosis kit can be used for early diagnosis of diseases and has wide application prospects in clinics.

The invention discloses a new application of Lycojaponicumin C in preparation of a medicine for treating hemorrhagic fever with renal syndrome. Experimental researches of Lycojaponicumin C in-vitro and in-vivo inhibition on virus of hemorrhagic fever with renal syndrome indicate that Lycojaponicumin C has low toxicity to cells, can directly kill virus of hemorrhagic fever with renal syndrome, can remarkably inhibit multiplication of the virus, and can obviously protect shrewmouse infected by the virus so as to delay the disease time, prolong the course of disease and reduce the death rate. Therefore, the Lycojaponicumin C is an effective and safe medicine for treating hemorrhagic fever with renal syndrome.

The invention discloses a new application of Lycojaponicumin B in preparation of a medicine for treating hemorrhagic fever with renal syndrome. Experimental researches of the Lycojaponicumin B in-vitro and in-vivo inhibition on virus of hemorrhagic fever with renal syndrome indicate that the Lycojaponicumin B has low toxicity to cells, can directly kill the virus of hemorrhagic fever with renal syndrome, can remarkably inhibit multiplication of the virus, and can obviously protect shrewmouse infected by the virus so as to delay the disease time, prolong the course of disease and reduce the death rate. Therefore, the Lycojaponicumin B is an effective and safe medicine for treating hemorrhagic fever with renal syndrome.

The invention discloses an application of aphanamixoid A in preparing a medicament for treating hemorrhagic fever with renal syndrome. Researches of aphanamixoid A in virus in-vitro and in-vivo inhibition experiments of hemorrhagic fever with renal syndrome indicate that the aphanamixoid A has low toxicity to cells, can directly kill virus of hemorrhagic fever with renal syndrome, can remarkably inhibit multiplication of the virus, and can remarkably protect susliks infected by the virus, so that the attack time is postponed, the disease course is prolonged, and the death rate is reduced. Therefore, the aphanamixoid A is an effective and safe medicament for treating hemorrhagic fever with renal syndrome.

The invention discloses a new application of Chukrasone B in preparation of a medicine for treating hemorrhagic fever with renal syndrome. Experiment researches on inhibiting hemorrhagic fever with renal syndrome virus by the Chukrasone B in vitro and in vivo show that the Chukrasone B has a low toxic effect on cells, has an effect of killing the hemorrhagic fever with renal syndrome viruses directly and can obviously inhibit the viruses from increasing, and the Chukrasone B has an obvious effect of protecting gophers infected by the virus, thus postponing the disease time, prolonging the course of disease and lowering the death rate. Therefore, the Chukrasone B is an effective and safe medicine for treating hemorrhagic fever with renal syndrome.

The invention discloses application of CIITA gene as a biomarker for diagnosis of dengue and dengue hemorrhagic fever. High-throughput screen is performed on genes having expression differences in normal people and patients with dengue and dengue hemorrhagic fever; large-sample reverse-transcription PCR (polymerase chain reaction) test proves that the content of CIITA gene in the blood of the patients with dengue and dengue hemorrhagic fever is lower than that in normal people. Therefore, the CIITA gene can serve as a biomarker for the diagnosis of dengue and dengue hemorrhagic fever. Researchresults herein provide a noninvasive method for the clinical early diagnosis of dengue and dengue hemorrhagic fever; the method is applicable to clinical popularization.

The invention discloses new application of Gypensapogenin B in preparing a medicine for treating hemorrhagic fever with renal syndrome. The research on experiments of inhibiting hemorrhagic fever virus with renal syndrome by Gypensapogenin B in vivo and in vitro indicates that Gypensapogenin B has low toxic effect on cells, has direct killing effect on hemorrhagic fever virus with renal syndrome, and can obviously restrain the proliferation of the viruses. Gypensapogenin B has obvious protective function to mice infected by the viruses, and has the functions of putting off the attack time, prolonging the course of the disease and reducing the death rate. Therefore, Gypensapogenin B is an effective and safe medicine for treating hemorrhagic fever with renal syndrome.

Diagnostic assays using IgE for detecting HIV in a baby patient or a child patient that might be infected with HIV; distinguishing between classic dengue and dengue hemorrhagic fever in a patient that is believed to have either the classic or hemorrhagic version of dengue; and detecting cognitive impairment in a patient who is more than 40 years old.

The invention discloses a prediction model for the incidence of hemorrhagic fever with renal syndrome, which belongs to the medical field. The steps are as follows: selecting a monitoring habitat, catching rats, calculating the poison index of rats, calculating the incidence of population, and building a prediction model. The problem that there is no prediction model for the incidence of hemorrhagic fever with renal syndrome in the prior art is solved. A method for accurately predicting the incidence regularity of hemorrhagic fever with renal syndrome is found by making direct use of a linearregression equation built based on the poison index of rats and the people's incidence of hemorrhagic fever with renal syndrome, and a scientific basis is provided for the prevention and control of hemorrhagic fever with renal syndrome.

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner. We show that epitope specific T cells can be activated in vivo in transgenic mice and in vitro in seropositive and seronegative individuals and that these T cells are functional, recognizing peptide pulsed and dengue virus infected cells in a pro-inflammatory and cytotoxic manner. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and may serve as a universal vaccine candidate complementary to current vaccines in trial.

The invention discloses a new application of Gypensapogenin A in preparation for a medicine for treating hemorrhagic fever with renal syndrome. Experimental studies on the in-vitro inhibition and the in-vivo inhibition of Gypensapogenin A for hemorrhagic fever with renal syndrome show that Gypensapogenin A has a low toxic effect on cells, plays a role of directly killing the virus of hemorrhagic fever with renal syndrome, can obviously inhibit the multiplication of the virus, and plays an obvious role of protecting hamsters infected with the virus so as to delay the onset time, prolong the disease course and decrease the mortality. Thus, Gypensapogenin A is an effective and safe medicine for treating the hemorrhagic fever with the renal syndrome.

The invention discloses a new application of Lycojaponicumin C in preparation of a medicine for treating hemorrhagic fever with renal syndrome. Experimental researches of Lycojaponicumin C in-vitro and in-vivo inhibition on virus of hemorrhagic fever with renal syndrome indicate that Lycojaponicumin C has low toxicity to cells, can directly kill virus of hemorrhagic fever with renal syndrome, can remarkably inhibit multiplication of the virus, and can obviously protect shrewmouse infected by the virus so as to delay the disease time, prolong the course of disease and reduce the death rate. Therefore, the Lycojaponicumin C is an effective and safe medicine for treating hemorrhagic fever with renal syndrome.

The invention discloses a gene marker for the early diagnosis of dengue and dengue hemorrhagic fever. The gene marker is an AKT1 gene. Whether a human subject suffers from the dengue and dengue hemorrhagic fever or whether the human subject has the risk of suffering from the dengue and dengue hemorrhagic fever is judged by detecting the levels of the AKT1 gene and an AKT1 protein in the blood of the human subject. A product for diagnosing the dengue and dengue hemorrhagic fever by detecting the content of the AKT1 gene or the AKT1 protein is developed according to the AKT1 gene and the AKT1 protein, and the diagnosis product can be popularized and used clinically.

The invention discloses a novel use of Polyflavanostilbene A in preparation of drugs for treating hemorrhagic fever with renal syndrome. Hemorrhagic fever with renal syndrome virus in-vivo and in-vitro inhibition experiments prove that Polyflavanostilbene A has low cell toxicity, has effects of directly killing hemorrhagic fever with renal syndrome viruses and obviously inhibiting hemorrhagic fever with renal syndrome virus multiplication, has an obvious function of protecting a hamster infected by the hemorrhagic fever with renal syndrome viruses, delays disease time, prolongs a course of the disease and reduces a death rate. Therefore, Polyflavanostilbene A is an effective and safe drug for treating hemorrhagic fever with renal syndrome.

The present invention discloses a prediction model of an annual incidence of a hemorrhagic fever with renal syndrome, belonging to the medical field. The technical scheme of the prediction model comprises the steps of: selecting a monitoring point, determining a patient, calculating L, calculating S, calculating W, measuring and calculating a determination coefficient 0.8S, and establishing a prediction model. The problem is solved that there is no a prediction model of an annual incidence of the hemorrhagic fever with renal syndrome in the prior art. The L, the S and the W are directly employed to establish the prediction model to explore a rule of accurately predicting the disease number of hemorrhagic fever with renal syndrome so as to provide a scientific basis for prevention and control work of the hemorrhagic fever with renal syndrome.

A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.

The invention discloses a diagnosis tool for dengue fever and dengue hemorrhagic fever. The diagnosis tool fulfills the aim of diagnosis by detecting a CACNB1 gene in blood and an expression product thereof. According to the invention, researches prove that compared to normal people, mRNA expression levels of the CACNB1 gene in blood of patients suffering from the dengue fever and the dengue hemorrhagic fever are obviously reduced. According to correlation between the CACNB1 gene and the dengue fever and the dengue hemorrhagic fever, a kit for diagnosing the dengue fever and the dengue hemorrhagic fever can be prepared; the kit can be widely clinically applied.

The invention discloses a method for preparing a dengue hemorrhagic fever virus II nucleic acid molecular characteristic standard sample. The dengue hemorrhagic fever virus II nucleic acid molecular characteristic standard sample is prepared according to the steps of synthesis of sequences, cloning of vectors, connection of target fragments and vectors, plasmid transformation, extraction and freezing dried storage of recombinant plasmids and the like. A standard sample that contains virus characteristic sequence information and is suitably used for analyzing the virus and the content thereof in a sample is prepared according to the method; the standard sample provided by the invention has good homogeneity, high stability and good purity, can be stored for long term, and is prepared according to the simple preparation method; a good standard sample is provided for detection research, medical research and the like of dengue hemorrhagic fever virus II type so as to achieve comparison of results from different laboratories and guarantee the quality control of laboratories; and a standard sample is also provided for fast and accurate detection of dengue hemorrhagic fever virus II type for inspection and quarantine institutions, import and export trade and the like.

The invention discloses novel application of Incarviatone A in preparation of a drug for treating hemorrhagic fever with renal syndrome. In-vitro and in-vivo inhibition experimental study on the effect of the Incarviatone A to hemorrhagic fever virus with renal syndrome shows that the Incarviatone A has low toxic effect on cells, has the direct killing effect on the hemorrhagic fever virus with renal syndrome, can obviously inhabit viral multiplication, has obvious protecting effect on susliks infected with the virus and enables the disease time to be postponed, the disease course to be prolonged and the death rate to be reduced. Therefore, the Incarviatone A is an effective and safe drug for treating the hemorrhagic fever with renal syndrome.